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Objectives: Systemic sclerosis (SSc) is a connective tissue disorder presenting fibrosis
of the skin and internal organs, for which no effective treatments are currently available.
Increasing evidence indicates that the P2X7 receptor (P2X7R), a nucleotide-gated
ionotropic channel primarily involved in the inflammatory response, may also have a key
role in the development of tissue fibrosis in different body districts. This study was aimed
at investigating P2X7R expression and function in promoting a fibrogenic phenotype
in dermal fibroblasts from SSc patients, also analyzing putative underlying mechanistic
pathways.
Methods: Fibroblasts were isolated by skin biopsy from 9 SSc patients and 8
healthy controls. P2X7R expression, and function (cytosolic free Ca2+ fluxes, α-smooth
muscle actin [α-SMA] expression, cell migration, and collagen release) were studied.
Moreover, the role of cytokine (interleukin-1β, interleukin-6) and connective tissue growth
factor (CTGF) production, and extracellular signal-regulated kinases (ERK) activation in
mediating P2X7R-dependent pro-fibrotic effects in SSc fibroblasts was evaluated.
Results: P2X7R expression and Ca2+ permeability induced by the selective P2X7R
agonist 2′-3′-O-(4-benzoylbenzoyl)ATP (BzATP) weremarkedly higher in SSc than control
fibroblasts. Moreover, increased αSMA expression, cell migration, CTGF, and collagen
release were observed in lipopolysaccharides-primed SSc fibroblasts after BzATP
stimulation. While P2X7-induced cytokine changes did not affect collagen production,
it was completely abrogated by inhibition of the ERK pathway.
Conclusion: In SSc fibroblasts, P2X7R is overexpressed and its stimulation induces
Ca2+-signaling activation and a fibrogenic phenotype characterized by increased
migration and collagen production. These data point to the P2X7R as a potential, novel
therapeutic target for controlling exaggerated collagen deposition and tissue fibrosis in
patients with SSc.
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INTRODUCTION
Systemic sclerosis (SSc; scleroderma) is a connective tissue
disease (CTD) presenting with three major aspects: small
vessel disease, autoantibody production, and fibroblasts
dysfunction leading to exaggerated deposition of collagen and
extracellular matrix (ECM), tissue fibrosis and organ dysfunction
(Allanore et al., 2015). Clinical aspects and prognosis of SSc
may diverge, most patients presenting skin thickening and
changeable involvement of internal organs including lungs,
heart, gastrointestinal tract, and kidneys (Allanore et al., 2015).
Although, relatively rare (50–300 case per million), the disease
has a relevant social impact since it typically affects young women
leading to significant disability and mortality (Allanore et al.,
2015). At the moment, no effective anti-fibrogenetic therapy is
available for the disease (Allanore et al., 2015; Pattanaik et al.,
2015).
Increasing evidence indicates that the purinergic system
may play a key role in the fibrotic process, by regulating
collagen and ECM production from the fibroblast. Although
most studies focused on P1 adenosine receptors (Chan et al.,
2006; Lazzerini et al., 2012; Perez-Aso et al., 2012, 2014),
recent data suggest that also P2 purinergic receptors, particularly
P2X7, may be actively involved in tissue fibrosis. The P2X7
receptor (P2X7R) is a nucleotide-gated ion channel chiefly
involved in the inflammatory response triggered by the
release of ATP from damaged cells. It is largely expressed in
monocytes where it enhances the synthesis and/or promotes the
release of lipopolysaccharide (LPS)-induced pro-inflammatory
cytokines, particularly interleukin-1β (IL-1β) and interleukin-18,
by activating the K+-dependent NALP3 inflammasome/caspase-
1 pathway (Di Virgilio, 2007; Castrichini et al., 2014; Gicquel
et al., 2015), but also possibly interleukin-6 (IL-6), via the Ca2+-
dependent MAP-Kinase/early growth response-1 gene systems,
egr-1 (Solini et al., 1999; Caporali et al., 2008; Friedle et al.,
2011). Accumulating data demonstrated that the P2X7R is also
expressed in fibroblastic cells (Solini et al., 1999; Caporali et al.,
2008; Friedle et al., 2011), promoting lung, kidney, pancreas, and
cardiac fibrosis in animal models (Gentile et al., 2015).
Starting from such premises, and taking into consideration
that no information exists on a possible role of P2X7R in
modulating fibrosis in scleroderma, we here hypothesized that
P2X7R activationmay stimulate the collagen biosynthetic process
in SSc fibroblasts, thus representing a potential pharmacological
target for the treatment of the disease. This study is aimed at
determining expression and function of the P2X7R by evaluating
calcium flux, α-SMA expression, cell migration, and collagen
production in human skin fibroblast from SSc patients as
compared to healthy controls.
MATERIALS AND METHODS
Skin Biopsies
Dermal fibroblasts were prepared from 5-mm skin biopsies from
the forearm of 9 SSc patients and 8 healthy volunteers matched
for age and sex. The research received the approval by the Local
Ethical Committee, and patients gave their informed consent in
accordance with the Declaration of Helsinki. Demography of the
subjects involved in the study is depicted in the Supplementary
Table.
Dermal Fibroblasts Isolation and Culture
Skin specimens were digested using 1 mg/ml clostridial
collagenase (Sigma-Aldrich, Milan, Italy) in phosphate buffered
saline (PBS). Cell suspensions were plated out in 10 ml of
Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with L-glutamine (2 mM), fetal bovine serum (FBS; 10%),
penicillin (200 U/ml) and streptomycin (200 µg/ml) in
100-mm culture dishes and incubated in a humidified
atmosphere containing 5% CO2. The experiments were
conducted at the third passage in order to avoid changes in
the original phenotype. Except where indicated otherwise,
all the reagents cited above were from Euroclone (Pero,
Italy).
Flow Cytometry Analysis of P2X7R
Expression
Fibroblasts (1 × 105) were incubated with a specific polyclonal
anti-P2X7R (extracellular) antibody fluorescein isothiocyanate
(FITC) (Sigma-Aldrich, Milan, Italy) (Xie et al., 2014) for 30
min at 4◦C. A rabbit IgG-FITC isotype control antibody was
chosen to differentiate non-specific background fluorescence
from specific antibody signal. Cells were analyzed with the Dako
Galaxy Flow Cytometry System and the FlowMax software.
The analysis was done on well-shaped living cells by setting
FSC X SSC live gates that exclude cellular debris. After setting
of appropriate gates 20,000 events were acquired for each
sample. The expression of surface-labeled P2X7Rs was evaluated
measuring both the percentage and the mean fluorescence
intensity (MFI) of cells that were P2X7R positive using the
FlowJo software, version 7.6.5. This analysis allows us to know
the percentage of fibroblasts expressing P2X7R with respect to
the total number of fibroblasts analyzed (% P2X7R+ cells) as
well as the level of P2X7Rs expression per single cell, evaluated
by its MFI.
Analysis of P2X7R mRNA by qRT-PCR
Total RNA was extracted from fibroblasts (1 × 106) using
the RNeasy Mini kit (Qiagen S.p.A, Milano, Italy) following
a standardized method (Del Ry et al., 2011). For cDNA
synthesis, iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA,
USA) was used according to the manufacturer’s instructions.
Specific primers for P2X7R were synthesized by Qiagen
(Hs_P2RX7_1_SG QuantiTect Primer Assay). Following recent
guidelines (Vandesompele et al., 2002), three candidate reference
genes [Eukaryotic translation elongation factor-1 alpha 1
(NM_001402), human ribosomal protein L13a (NM_012423)
and ribosomal protein S4, X-Linked (NM_002046)], from among
the most commonly cited in the literature, were selected and used
to normalize mRNA expression data obtained by Real-Time PCR
experiments. More details are provided in the Supplementary
Material.
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P2X7R-Induced Calcium Influx
Measurement
P2X7R is an ATP-gated cation channel. It acts as a bifunctional
molecule whose brief activation causes the rapid (within
milliseconds) and reversible opening of a channel selective for
small cations, that induces the entry of Ca2+ and Na+ and the
efflux of K+ while a sustained stimulation causes the opening
of a larger pore. From a physiological point of view, it has been
demonstrated that the channel openingmediates the effects of the
P2X7R on cytokine production, in particular IL-1β maturation
and release (triggered by the K+ efflux), and IL-6 expression
(activated by the Ca2+ influx; North, 2002; Di Virgilio, 2007;
Friedle et al., 2011). In the present study we studied the P2X7R
functional activation in terms of Ca2+ influx, evaluated by the
analysis of the cytosolic Ca2+ ([Ca2+]i) elevation. Indeed, since
both Ca2+ influx and K+ efflux results from the opening of the
same cationic channel, Ca2+ measurement was here employed
as a marker more in general reflecting the extent of P2X7R (and
related intracellular pathways) activation.
P2X7R activation was induced by using 2′-3′-O-(4-
benzoylbenzoyl)ATP (BzATP) a selective P2X7R synthetic
agonist that exhibits 10 fold greater potency respect to the
physiological activator ATP (Jacobson, 2010). Technical details
are provided as Supplementary Material.
In order to describe the features of Ca2+ influx, the following
parameters were measured: (i) the Area Under the Curve (AUC)
as an expression of the area included under the curve of the
[Ca2+]i over the time for 5 min following the agonist addition
[AUC (5′)] and (ii) the percentage (%) of responsive cells.
Culture Stimulation
Dermal fibroblasts were plated out in 500 µl of starvation
medium (DMEM plus 0.5 % FBS). After 24 h in starvation, cells
were primed with lipopolysaccharide (LPS, 1 µg/ml) from E. coli
026:B6 or vehicle for 24 h, and then stimulated with the P2X7R
agonist BzATP (0.1 mM) for 30 min. Cells were also stimulated
with LPS alone.
In order to confirm the specific involvement of the P2X7R
in the observed effects, experiments with two different synthetic
P2X7R antagonists were performed, by incubating for 2 h the
LPS-primed cells with oxidized ATP (oATP, 200µM) or A438079
(10–50 µM) before BzATP treatment.
The putative effects of IL-6 released by SSc fibroblasts upon
P2X7R activation was investigated adding the recombinant
human soluble IL6 receptor (IL6α, 10 ng/ml) to the BzATP+LPS-
stimulated cells for 24 h.
Finally, the involvement of ERK-1/2 pathway in P2X7R
activation-induced collagen production was evaluated by pre-
treatement of the fibroblasts with the selective ERK-1/2 inhibitor
FR-180204 (50 µM) for 30 min before BzATP+LPS stimulation.
LPS, BzATP, and oATP were purchased from Sigma-
Aldrich (Milan, Italy). FR-180204, A438079 and soluble IL-
6Rα from Tocris (Bristol, UK). Reagents were dissolved in
dimethyl sulfoxide (DMSO, Sigma-Aldrich, Milan, Italy) or in
distilled water. Accordingly, fibroblast cultures treated with the
appropriate vehicle were used as basal samples.
Collagen Analysis
Collagen concentration was determined in the supernatant of the
cells collected at the end of each treatment and stored at −20◦C
until used. By means of the EIA kit (Takara Bio Inc., Otsu, Japan)
we evaluated the procollagen type I carboxy-terminal peptide
(PIP) released in the culture supernatants as an expression of the
collagen synthesis. PIP levels were measured as ng/ml. Technical
details are reported as Supplementary Material.
Immunofluorescence Experiments
Fibroblasts were seeded on 13 mm glass coverslip and stimulated
or not with LPS and BzATP in the presence or in the absence
of A438079 (50 µM), as described in culture stimulation section.
The cells were then fixed with paraformaldehyde 4% for 15′ at
RT and permeabilized with Triton X-100 0.1% for 10′ at RT.
After blocking with 1%BSA, 10% goat serum, 0.1% Tween-20
and 2 mM EDTA for 1 h at RT, the cells were incubated with
a mouse anti-α smooth muscle actin (αSMA) antibody (Sigma-
Aldrich, Saint Louis, MO, USA) 1:200, overnight at 4◦C and then
reacted with a goat anti-mouse cy3 1:5000 (Jackson Laboratories,
Bar Harbor, ME). Nuclei were visualized by 4′,6-diamidino-2-
phenylindole (DAPI, Sigma-Aldrich). After mounting the cells
were examined in a fluorescence microscope Nikon Eclipse Ti
coupled to a DS-Q1Mc camera and a NIS element software
(Nikon, Tokio, Japan).
Scratch Wound Healing Assay
Fibroblasts were plated onto 24-well plates allowed to grow
to confluency in the same medium as for cell culture. Once
confluent, the medium was switched to starvation medium
(DMEM plus 0.2% FBS) for 24 h to minimize the influence of
hormones and growth factors. After the starvation period, the
cells were scratched with a 200 µl pipette tip, washed two times
with PBS to remove cellular debris after that treatments were
applied.Wells were imaged at 0 and 48 h at 4x magnification with
phase contrast Zeiss Axiocam. Image J was used to measure the
area of the scratch remaining at the different time points. The
free hand tool on Image J was used to draw around the scratch
and area in mm2 was measured after setting the field of view to
3,400× 2,700 µm.
Cytokine Supernatant Assay
IL-1β and IL-6 cytokines release was analyzed in the culture
supernatants using commercially available Bio-Plex-Pro Human
Cytokine assay (BioRad Laboratories, Hercules, CA) according
to the manufacturer’s protocol. Sample were acquired by a Bio-
Plex 200 system and after setting up the calibration the cytokines
concentration were performed using the Bio-Plex Manager
software v5.0 (BioRad).
Connective Tissue Growth Factor (CTGF)
Supernatant Assay
CTGF concentration was measured in duplicate in culture
supernatants of dermal fibroblasts from healthy controls and SSc
patients after different treatments, by using the Human CTGF
ELISA Kit (Cloude-Clone Corp., TX, USA) according to the
manufacturer’s instructions.
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FIGURE 1 | P2X7R surface expression is increased in SSc dermal fibroblasts. (A–C) P2X7R surface expression in dermal fibroblasts from SSc patients and HC, as
determined by flow cytometry: (A) original flow cytometry data representative of an experiment; (B) percentage of P2X7R positive cells, and (C) MFI values. SSc
patients, n = 6; HC, n = 5. *p < 0.05, two-tailed unpaired t-test; **p < 0.01, two-tailed Mann–Whitney test. (D) P2X7R mRNA expression in dermal fibroblasts from
SSc patients and HC, as determined by quantitative RT-PCR analysis. SSc patients, n = 7; HC, n = 6. p = not significant, two-tailed unpaired t-test. SSc, Systemic
sclerosis; HC, healthy controls; P2X7R, P2X7 receptor; MFI, mean fluorescence intensity; RT-PCR, reverse transcription-polymerase chain reaction.
Statistical Analysis
All experiments were performed in duplicate or triplicate.
Normal distribution of quantitative variables was preliminarily
tested using the Kolmogorov–Smirnov test to select parametric
(normal distribution) or non-parametric (non-normal
distribution) inferential statistical methods. Accordingly,
the following parametric or non-parametric statistical analyses
were performed, respectively: the two-tailed unpaired t-test or
the two-tailed Mann–Whitney test to evaluate differences in
continuous variables between two groups. The repeatedmeasures
analysis of variance (RM-ANOVA) and the two-tailed Tukey–
Kramer post-hocmultiple comparisons test, or the Friedman test
(non-parametric RM-ANOVA), or Kruskal–Wallis test (one-way
non-parametric ANOVA) and the two-tailed Dunn’s post-hoc
multiple comparison test to evaluate differences in continuous
variables among more than two groups. Values of p < 0.05 were
considered significant. All statistical analyses were done using
GraphPad-InStat package (GraphPad, La Jolla, CA, USA).
RESULTS
P2X7R Surface Expression Is Increased in
SSc Dermal Fibroblasts
Flow cytometry analysis showed that the P2X7R was expressed
on the surface of both healthy and SSc dermal fibroblasts
(Figures 1A–C). However, both the percentage of P2X7-positive
cells (46± 7 vs. 35± 6%, p= 0.023; Figure 1B) and, particularly,
the total amount of the P2X7R expressionwas significantly higher
in SSc than healthy fibroblasts, as demonstrated by the ∼3-times
higher values of mean fluorescence intensity (MFI; 6.5 ± 2.6 vs.
2.2± 0.3, p= 0.0087; Figure 1C).
Such a phenomenon was not associated with an increased
P2X7R gene expression by the cells, as real time-PCR analysis
indicated that the levels of P2X7R mRNA were not significantly
different in SSc patients when compared to healthy controls (2.6
± 2.5 vs. 1.9± 1.1 fold-increase, p= 0.58; Figure 1D).
P2X7R-Mediated Calcium Influx Is
Enhanced in Dermal Fibroblasts from SSc
Patients
P2X7R stimulation with the receptor agonist BzATP resulted
in calcium influx in normal and SSc dermal fibroblasts in the
presence of extracellular Ca2+ (Figure 2A). However, significant
differences between the two cell populations were found,
indicative of an increased P2X7-dependent Ca2+ permeability in
SSc fibroblasts. In fact, both the number of responding cells (54
± 22 vs. 16± 7%, p= 0.0095; Figure 2C), and the extent of Ca2+
uptake as assessed by the AUC (9,527 ± 3,396 vs. 1,293 ± 477
nM, p = 0.0093; Figure 2B) were significantly higher when SSc
cells were compared to healthy subject fibroblasts. Notably, pre-
incubation of SSc fibroblasts with the P2X7R antagonist oATP
significantly reduced BzATP-induced calcium influx, to values
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FIGURE 2 | P2X7R-mediated calcium influx is enhanced in dermal fibroblasts from SSc patients. BzATP-induced calcium entry in dermal fibroblasts from SSc
patients and HC, as determined by single-cell fluorescence microscopy. (A) Representative plot of an experiment in one SSc patient (a,c) and one HC (b,c). Each
colored trace in (a,b) represents the response of individual cells while the thick black line in (a,b), and the red and black lines in (c) represent the mean response of all
the cells from the same culture dish. The arrow indicates the time when the agonist was added. (B) P2X7-induced Ca2+ uptake as assessed by the AUC 5′, in
dermal fibroblasts from SSc patients and HC. SSc patients, n = 6; HC, n = 4. **p < 0.01, two-tailed Mann–Whitney test. (C) Percentage of BzATP-responsive cells in
SSc patients and HC. SSc patients, n = 6; HC, n = 4. **p < 0.01, two-tailed Mann–Whitney test. SSc, Systemic sclerosis; HC, healthy controls; P2X7R, P2X7
receptor; Bz, 2′-3′-O-(4-benzoylbenzoyl)ATP; Ca2+, calcium; AUC 5′, area under the curve represents the area enclosed between the curve of the [Ca2+]vs. the time
for 5 min after the addition of the stimulus.
substantially comparable to controls (number of responding cells:
13±21%, p = 0.015; AUC: 2,342 ± 1,280 nM, p = 0.0003;
Figure 3).
P2X7R Activation Stimulates Collagen
Production in SSc Dermal Fibroblasts
In LPS-primed fibroblasts from SSc patients, BzATP-dependent
P2X7R activation resulted in a clear-cut stimulation of collagen
synthesis. As shown in the Figure 4, while cell stimulation with
LPS or BzATP alone produced no changes in PIP release, LPS
plus BzATP significantly increased supernatant PIP levels in SSc
dermal fibroblasts (466.0 ± 313.9 vs. 277.0 ± 183.1 ng/ml in
untreated cells, +76.7%; p < 0.05). This effect was not due to an
increase in cells number after stimulation (62 ± 17.6 vs. 62.89
± 22.8 cells/microscopic field analyzed in parallel experiments).
Such a stimulating effect was completely removed when cultures
were co-incubated with the P2X7R antagonist, oATP (Figure 5).
On the contrary, none of the treatments induced appreciable
effects on collagen synthesis in healthy subject cells.
P2X7R Stimulation Increases αSMA
Bundles Expression in SSc Dermal
Fibroblasts
Differentiation of fibroblast into myofibroblast can be
marked by several morphological and functional changes,
including cell dimension increase, collagen production
and expression of contractile proteins such as αSMA.
In particular, a well-recognized characteristic of the fully
differentiated myofibroblast is the accumulation of cytoplasmatic
microfilaments constituted by αSMA bundles (stress fibers)
with high contractile activity (Talele et al., 2015; Garrett et al.,
2017).
In basal conditions, healthy fibroblasts had a very weak
reaction for αSMA when compared to SSc dermal fibroblasts
(Figure 6). However, despite showing a high fluorescence
intensity, SSc cells displayed a heterogeneous αSMA staining
represented by a punctate and bundled pattern, with a prevalence
of cells with punctate distribution (63 ± 24% of cells counted
in at least five random fields of 3 separate coverslips for each
of 4 different patients). P2X7R stimulation with LPS + BzATP
markedly increased the percentage of large-size fibroblasts
expressing well-developed αSMA microfilament bundles (from
37± 24 to 84± 14%; p< 0.05). Conversely, in the presence of the
P2X7R inhibitor A438079, the percentage of αSMA stress fiber-
positive cells significantly fell below the basal levels (19 ± 14%;
Figure 6), thus suggesting a constitutive activity of the receptor
in the SSc fibroblast. Culture stimulation with LPS + BzATP
induced a slight increase of αSMA stress fiber-positive cells also
in healthy fibroblasts (from 16± 4 to 30± 14%), an effect which
was completely prevented by A438079 pre-incubation (15 ± 8%;
Figure 6).
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FIGURE 3 | P2X7R antagonism inhibits calcium influx in SSc dermal fibroblasts. Effect of the P2X7R antagonist oxATP (200 µM) on BzATP-induced calcium entry in
dermal fibroblasts from SSc patients, as determined by single-cell fluorescence microscopy. (A) Representative plot of an experiment in one SSc patient (a,b). Each
colored trace in (a) represents the response of individual cells while the thick black line in (a,b) represent the mean response of all the cells from the same culture dish.
The arrow indicates the time when the agonist was added. (B) P2X7-induced Ca2+ influx in dermal fibroblasts from SSc patients (n = 5) pre-incubated with oATP, as
assessed by the AUC 5′. ***p < 0.01, two-tailed paired t-test. (C) Percentage of BzATP-responsive cells in SSc patients (n = 5) pre-incubated with oATP. *p < 0.05,
two-tailed paired t-test. SSc, Systemic sclerosis; P2X7R, P2X7 receptor; Bz, 2′-3′-O-(4-benzoylbenzoyl)ATP; oATP, oxidized ATP; Ca2+, calcium; AUC 5′, area under
the curve represents the area enclosed between the curve of the [Ca2+]vs. the time for 5 min after the addition of the stimulus.
P2X7R Stimulation Increases SSc Dermal
Fibroblasts Migration
As predicted by the enhanced expression of contractile proteins,
wound healing experiments performed in vitro by using a scratch
assay demonstrated that P2X7R also increased SSc fibroblast
migration. After LPS priming, P2X7R stimulation with BzATP
promoted wound healing as demonstrated by the increased SSc
cell migration to closing the wound scratch (Figures 7A,B).
This view was further confirmed by the evidence that culture
co-incubation with the P2X7R-inhibitor A438079 completely
abrogated the effect (Figures 6A,B).
P2X7R Activation Induces IL-6, But Not
IL-1β, Release from SSc Dermal
Fibroblasts
In order to provide information about the possible intracellular
mechanisms involved in P2X7R-dependent collagen production
in LPS-primed SSc dermal fibroblasts, we evaluated whether
the LPS plus BzATP co-incubation was associated with the
production of specific cytokines, particularly IL-1β and IL-6,
as a possible result of the P2X7R-induced activation of the
K+-dependent NALP3 inflammasome/caspase-1 or the Ca2+-
dependent MAP-Kinase/egr-1 systems, respectively. As shown in
Figures 8A,B, while no changes in IL-1β were observed (0.07 ±
0.02 vs. 0.09 ± 0.02 pg/ml; p = 0.41), co-treatment of SSc cells
with LPS+ BzATP induced a significant 2.4-fold increase in IL-6
supernatant levels (2.5± 2.6 vs. 6.0± 3.0 pg/ml; p= 0.0032).
IL-6 Does Not Contribute to
P2X7R-Dependent Collagen Production
from SSc Dermal Fibroblasts
Since human dermal fibroblasts (thus SSc fibroblasts) do not
express on their surface the IL-6 receptor (transmembrane IL-6R,
mIL-6R) required for activating classic signaling (Lazzerini et al.,
2016), the possibility can be ruled out that the P2X7-dependent
stimulating effect on collagen production observed in-vitro is
the result of the above reported IL-6 increase, via an autocrine
mechanism. Nevertheless, we evaluated the potential additive
role of the P2X7R-dependent IL-6 increase in enhancing collagen
production from SSc fibroblast via the soluble IL-6R (sIL-6R)-
dependent transsignaling pathway, potentially relevant in SSc
patients in-vivo. In fact, differently from in vitro conditions,
the sIL-6R is freely available in vivo in human plasma where
it is released by hepatocytes, leukocytes and megakaryocytes
(Lazzerini et al., 2016). On these premises, LPS-primed SSc
fibroblasts were stimulated with BzATP in the presence of sIL-
6R, but no any further increase in collagen supernatant levels was
observed (Figure 8C).
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FIGURE 4 | P2X7R activation stimulates collagen production in SSc dermal
fibroblasts. Spontaneous, Bz-, LPS-, and Bz+LPS-induced PIP release in the
culture medium of dermal fibroblasts from SSc patients and HC. Cells starved
for 24 h were primed with LPS (1 µg/ml) or vehicle for further 24 h, and then
stimulated with Bz (0.1 mM) for 30 min; cells were also stimulated with LPS
alone (24 h). SSc patients, n = 6; HC, n = 5. Comparisons within SSc
patients: RM-ANOVA, p = 0.0064; post-hoc two-tailed Tukey–Kramer test,
*p < 0.05, **p < 0.01. Comparisons within HC: Friedman test (non-parametric
RM-ANOVA), p = not significant. Comparison between SSc patients and HC:
†
p < 0.05, two-tailed Mann–Whitney test. SSc, Systemic sclerosis; HC,
healthy controls; P2X7R, P2X7 receptor; B, baseline; Bz,
2′-3′-O-(4-benzoylbenzoyl)ATP; LPS, lipopolysaccharide; PIP, procollagen
type I carboxy-terminal peptide; RM-ANOVA, repeated measures analysis of
variance.
FIGURE 5 | P2X7R antagonism inhibits collagen production in SSc dermal
fibroblasts. Effect of the P2X7R antagonist oATP (200 µM) on
Bz+LPS-induced PIP release in the culture medium of dermal fibroblasts from
SSc patients, as determined by EIA assay. SSc patients, n = 5. RM-ANOVA,
p = 0.0052; post-hoc two-tailed Tukey–Kramer test, *p < 0.05, **p < 0.01.
SSc, Systemic sclerosis; HC, healthy controls; P2X7R, P2X7 receptor; B,
baseline; Bz, 2′-3′-O-(4-benzoylbenzoyl)ATP; LPS, lipopolysaccharide; oATP,
oxidized ATP; PIP, procollagen type I carboxy-terminal peptide; RM-ANOVA,
repeated measures analysis of variance.
P2X7R Activation Induces CTGF Release
from Dermal Fibroblasts
The possible pathway involved in mediating P2X7R-induced SSc
fibroblast activation was then further investigated by evaluating
FIGURE 6 | P2X7R activation promotes myofibroblast differentiation of SSc
dermal fibroblasts. Effect of Bz+LPS stimulation on the differentiation of dermal
fibroblasts to myofibroblasts, identified as large size and αSMA bundle (stress
fiber)-positive cells by immunofluorescence. Fibroblasts from SSc patients and
HC were starved for 24 h and then primed with LPS (1 µg/ml) or vehicle for
further 24 h, followed by stimulation with Bz (0.1 mM) for 30 min, alone or after
2 h pre-incubation with the P2X7R antagonist A438079 (50 µM). (A)
Representative figure of an experiment performed in SSc and HC fibroblasts,
respectively: in red the immunofluorescence for α-SMA, while nuclei were
stained in blue with DAPI. Images were acquired with a 60X/1.49 Apo
objective. (B) Effect of Bz+LPS and Bz+LPS+AR438079 on myofibroblast
differentiation, as determined by the percentage of αSMA stress fiber-positive
cells. Histograms represent results (mean ± standard deviation) of
experiments performed by using fibroblasts from SSc patients (n = 4) and HC
(n = 3). RM-ANOVA, p = 0.012; post-hoc two-tailed Tukey–Kramer test, *p <
0.05, **p < 0.01. P2X7R, P2X7 receptor; SSc, Systemic sclerosis; B, baseline;
Bz, 2′-3′-O-(4-benzoylbenzoyl)ATP; LPS, lipopolysaccharide; HC, healthy
controls; DAPI, 4′,6-diamidino-2-phenylindole; ANOVA, analysis of variance.
the effect of LPS + BzATP stimulation on the release of CTGF
in the culture supernatant. Under these conditions, CTGF levels
showed a clear-cut increase (∼6-fold, from 13.9 ± 6.3 to 91.6
± 36.7 pg/ml) which was completely abrogated by culture pre-
incubation with the P2X7 antagonists oATP (15.4 ± 0.4 pg/ml)
or A438079 (50 µM: 13.9 ± 5.4 pg/ml; 10 µM:13.6 ± 1.8 pg/ml;
Figure 9). CTGF release was also affected in healthy fibroblasts,
although to a lesser extent: culture stimulation with LPS+BzATP
induced a∼2-fold CTGF increase (from 16.0± 0.4 to 27.4± 6.9
pg/ml), an effect which was completely prevented by oATP (13.4
± 3.1 pg/ml) or A438079 (50 µM: 13.5± 2.5 pg/ml; 10 µM: 18.9
± 4.8 pg/ml) pre-incubation (Figure 9).
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FIGURE 7 | P2X7R stimulation increases SSc fibroblasts migration. P2X7R-dependent migration of SSc dermal fibroblasts, as determined by in vitro scratch-wound
healing assays. (A) (a) Representative figure of an experiment. Cells are stimulated with Bz+LPS alone or in association with the P2X7R antagonist A438079 (50 µM).
Photos were taken immediately after wounding (0 h) and 48 h later. Yellow vertical lines show the scratch area, as initially measured at 0 h. (b) Magnification of the
scratch area at 48 h. (B) Effect of Bz+LPS and Bz+LPS+AR438079 on SSc dermal fibroblast migration, as determined by the scratch area at 48 h. Plots represent 5
different experiments performed by using fibroblasts from 3 different SSc patients. Kruskal–Wallis test (non-parametric ANOVA), p = 0.0083; post-hoc two-tailed Dunn
multiple comparison test, *p < 0.05. SSc, Systemic sclerosis; P2X7R, P2X7 receptor; B, baseline; Bz, 2′-3′-O-(4-benzoylbenzoyl)ATP; LPS, lipopolysaccharide;
ANOVA, analysis of variance.
ERK-1/2 Inhibition Completely Prevents
P2X7R-Induced Collagen Production in
SSc Dermal Fibroblasts
Increasing evidence indicates that LPS-besides constituting an
essential stimulus for the activation of the NALP3 inflammasome
via a Toll-like receptor-mediated mechanism- can also directly
interact with the P2X7R by recognizing a sequence of the
carboxy-end which contains a conserved LPS-binding domain
(Denlinger et al., 2001). This interaction is required to
induce LPS-dependent activation of the extracellular signal-
regulated kinases (ERK1, ERK2; Denlinger et al., 2001), which
in turn are involved in SSc fibroblast activation leading to
collagen production (Bogatkevich et al., 2007; Chen et al.,
2008). Thus, we evaluate the possible involvement of this
pathway as the intracellular mechanism linking P2X7R and
collagen production in LPS-primed SSc fibroblasts by pre-
treating the cells with the ERK-1/2 inhibitor, FR-180204.
Figure 10 shows that the addition of this molecule to the
cultures completely abrogated the P2X7R-dependent stimulating
effect on collagen production, as assessed by supernatant PIP
levels.
Notably, also P2X7R-induced CTGF release was fully reversed
when fibroblast cultures were pre-incubated with FR-180204
(Figure 9).
DISCUSSION
The main findings of the present study are the following: (i)
when compared to healthy controls, dermal fibroblasts from
SSc patients display a higher P2X7R surface expression with
an enhanced function in terms of Ca2+ influx; (ii) in LPS-
primed SSc fibroblasts, P2X7R stimulation results in profibrotic
effects by promoting enhanced αSMA expression, cell migration,
CTGF, and collagen production; (iii) intracellular mechanisms
underlying P2X7R-induced fibrogenic effects seem to involve a
cytokine-independent pathway likely due to ERK-1/2 signaling
activation. Altogether, these data point to the P2X7R as a
potential, novel therapeutic target for controlling exaggerated
collagen deposition and tissue fibrosis in patients with SSc.
The P2X7 protein is a 595 amino acids sequence consisting
of an intracellular N-terminus, two hydrophobic transmembrane
domains, an extracellular loop, and an intracellular C-terminus
(North, 2002). The main structurally distinctive feature of the
P2X7R is a long C-terminal tail (244 amino acids) that is essential
for pore formation, receptor trafficking and stabilization of the
P2X7R in the membrane. Moreover, it harbors multiple potential
protein and lipid interaction motifs (Vandesompele et al., 2002;
Smart et al., 2003). Although the most recognized role of P2X7R
is the promotion of effector functions inmonocytes/macrophages
(cell proliferation, killing, nuclear factor-kB activation, cytokine
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FIGURE 8 | P2X7R activation induces IL-6 release from SSc dermal
fibroblasts, but the cytokine does not contribute to collagen production. (A)
Effect of Bz+LPS stimulation on the IL-1β release in the culture medium of
dermal fibroblasts from SSc patients; n = 7. p = not significant, two-tailed
paired t-test. (B) Effect of Bz+LPS stimulation on the IL-6 release in the culture
medium of dermal fibroblasts from SSc patients; n = 7. **p < 0.01, two-tailed
paired t-test. (C) Effect of the addition of the sIL-6R on Bz+LPS-induced PIP
release in the culture medium of dermal fibroblasts from SSc patients, as
determined by EIA assay; n = 6. RM-ANOVA, p = 0.023; post-hoc two-tailed
Tukey–Kramer test, *p < 0.05. SSc, Systemic sclerosis; P2X7R, P2X7
receptor; B, baseline; Bz, 2′-3′-O-(4-benzoylbenzoyl)ATP; LPS,
lipopolysaccharide; IL-1β, interleukin-1β; IL-6, interleukin-6; sIL-6R, soluble
interleukin-6 receptor; PIP, procollagen type I carboxy-terminal peptide;
RM-ANOVA, repeated measures analysis of variance.
FIGURE 9 | P2X7R stimulation induces CTGF release from dermal fibroblasts,
which is completely abrogated by P2X7R antagonism or ERK-1/2 inhibition.
Effect of Bz+LPS stimulation on CTGF release in the culture medium of dermal
fibroblasts from SSc patients (n = 2) and healthy controls (n = 2), as
determined by ELISA assay, and its modulation by P2X7R antagonists (oATP
200 µM; A438079 10–50 µM) or an ERK-1/2 inhibitor (FR-180204 50 µM).
CTGF, connective tissue growth factor; SSc, Systemic sclerosis; P2X7R, P2X7
receptor; B, baseline; Bz, 2′-3′-O-(4-benzoylbenzoyl)ATP; LPS,
lipopolysaccharide; oATP, oxidized ATP; A43[50], A438079 50 µM; A43[10],
A438079 10 µM; FR, FR-180204.
production, and release; Rossi et al., 2012) resulting in an
amplification of the innate immune response, increasing recent
FIGURE 10 | ERK-1/2 inhibition completely prevents P2X7R-induced collagen
production in SSc dermal fibroblasts. Effect of the ERK-1/2 inhibitor
FR-180204 (50 µM) on Bz+LPS-induced PIP release in the culture medium of
dermal fibroblasts from SSc patients, as determined by EIA assay. SSc
patients, n = 4. RM-ANOVA, p = 0.013; post-hoc two-tailed Tukey–Kramer
test, *p < 0.05. SSc, Systemic sclerosis; P2X7R, P2X7 receptor; ERK-1/2,
extracellular signal-regulated kinases-1/2; B, baseline; Bz,
2′-3′-O-(4-benzoylbenzoyl)ATP; LPS, lipopolysaccharide; FR, FR-180204; PIP,
procollagen type I carboxy-terminal peptide; RM-ANOVA, repeated measures
analysis of variance.
evidence suggests that this receptor may also be actively involved
in wound healing by stimulating reparation and fibrosis. Indeed,
several studies have demonstrated that the P2X7R is expressed
by a wide range of fibroblastic cells throughout the body, both
in animals [heart (Kumagai et al., 2013), kidney (Ponnusamy
et al., 2011), pancreas (Haanes et al., 2012), endometrium
(Koshi et al., 2005)] and in humans [skin (Solini et al., 1999),
synovium (Caporali et al., 2008), gingival, and dental pulp
tissue (Jiang et al., 2015)]. In addition, increasing data from
animal models indicate that P2X7R activation plays a key role
in different forms of experimental fibrotic diseases. Gonçalves
et al. (2006) demonstrated that kidneys from P2X7R-knockout
(KO) mice with unilateral ureteral obstruction showed a lower
immunostaining for transforming growth factor-β (TGF-β), and
myofibroblasts when compared with wild-type mice. Moreover,
P2X7R-KO mice airway-administered with bleomycin to induce
lung fibrosis, presented dramatically reduced fibrosis markers,
such as lung collagen content and matrix-remodeling proteins,
than in control animals normally expressing the receptor
(Riteau et al., 2010). More recently, beneficial effects of P2X7R
antagonism on liver fibrosis were reported both in rats with bile
duct ligation-induced cirrhosis, (Tung et al., 2015) and in mice
with carbon tetrachloride-induced liver fibrosis (Huang et al.,
2014). Keeping this in mind, we characterized the expression and
function profile of the P2X7R in dermal fibroblasts from patients
with SSc, a systemic fibrotic disorder of unknown origin, to test
the hypothesis that a dysregulation of this receptor may play a
role in this disease.
A first relevant finding from our study is the demonstration
that in SSc dermal fibroblasts the surface expression of the
P2X7R is substantially increased. In fact, both the percentage of
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P2X7-positive cells and the mean number of receptors expressed
on the cell membrane, as indicated by the MFI values, was
significantly higher in fibroblasts from SSc patients than healthy
controls. These data confirm and expand preliminary data from
a seminal work from the group of Di Virgilio (Lo Monaco et al.,
2007), in which for the first time evidence was provided that
SSc dermal fibroblasts expressed mRNA for several P2 receptors,
including the P2X7R; however, these authors did not perform any
quantitative comparison with control cells. Indeed, in our study
we found no significant difference in fibroblast P2X7R-mRNA
content between SSc patients and healthy subjects, a datum
suggesting that P2X7R up-regulation does not involve gene
transcription but only cell surface expression of the molecule,
possibly via an increased trafficking of the P2X7R protein to
the plasma membrane. Indirect support to this view is provided
by previous data on monocytes/macrophages. Gudipaty et al.
(2001) demonstrated that during cytokine-driven differentiation
in macrophages healthy human monocytes markedly increase
the P2X7R number per cell (MFI > 10-fold) without any
significant change in the mRNA content. Moreover, we found
that monocytes from patients with a chronic inflammatory
disorder such as Behçet’s disease expressed significantly higher
P2X7Rmembrane levels than healthy controls, with no difference
in intracellular mRNA concentration (Castrichini et al., 2014).
Notably, Gu et al. (2000) demonstrated that in monocytes from
healthy humans most of P2X7R protein is localized inside the
cell roughly an order of magnitude greater than that expressed
on the membrane. On this basis, the authors hypothesized
that this intracellular pool represents a reserve able to be
recruited to the surface when the cell activates. Probably such a
mechanism is operative also in SSc fibroblasts, thus explaining
the high cell membrane P2X7R expression found in these
patients.
Not only the expression, but also the function of the P2X7R
as evaluated by agonist-induced Ca2+ influx, αSMA expression,
cell migration, CTGF, and collagen release, was enhanced in SSc
dermal fibroblasts.
As regards the P2X7R-dependent Ca2+ influx, a significantly
higher ion permeability was observed in SSc patients when
compared to healthy controls. In particular, SSc fibroblasts
showed an enhanced reactivity to BzATP, a potent and selective
synthetic P2X7R agonist, as demonstrated by the higher
percentage of responsive cells, and the increased total amount of
Ca2+ entry into the single cell in the time unit, as reflected by
AUC 5′-values. Such results, together with the evidence that SSc
fibroblast hyper-responsiveness significantly reduced after oATP
pre-incubation, strongly support the active role of the P2X7R in
the function of these cells.
Notably, these findings paralleled the differences in the
expression pattern observed between the two groups, i.e., SSc
fibroblasts expressed higher levels of P2X7R on a higher number
of cells when compared to controls, thus suggesting that P2X7R
overexpression is the main driver of receptor overactivity.
In agreement with our data, a preliminary observation by
Lo Monaco et al. (2007) found that SSc dermal fibroblasts
showed an increased sensitivity to extracellular ATP than healthy
controls in terms of intracellular Ca2+ changes. Moreover, some
recent studies reported that P2X7R function was increased in
peripheral blood mononuclear cells (PBMC) from patients with
other autoimmune diseases, specifically rheumatoid arthritis (Al-
Shukaili et al., 2008, 2011), and Behçet’s disease (Castrichini
et al., 2014). In particular, Al-Shukaili et al. (Al-Shukaili et al.,
2008, 2011) demonstrated that in rheumatoid arthritis patients
the increase in the P2X7R function, without any concomitant
membrane expression enhancement, was associated to a higher
prevalence of a gain-of-function receptor gene polymorphism
in these subjects. Conversely, our data are poorly consistent
with the hypothesis that SSc-associated changes in the receptor
function are the result of a specific genetic substrate. In fact,
currently known gain of function polymorphisms influence
receptor properties without any appreciable significant effect
on the membrane expression (Sun et al., 2010). Nevertheless,
a novel single-nucleotide polymorphism (H155Y) enhancing
P2X7R function via increased protein trafficking and surface
expression has been recently identified (Bradley et al., 2011).
Thus, this theoretical possibility cannot be completely ruled out.
Exaggerated fibroblast activation, as reflected by increased
cell proliferation, migration, production of ECM proteins and
collagen, represents a key feature in the pathogenesis of SSc
(Allanore et al., 2015). Our data provide for the first time
evidence that P2X7R may be actively involved in promoting this
process. In fact, SSc fibroblast stimulation with selective receptor
agonists resulted in a clear-cut increase in the myofibroblast
phenotype, with higher propensity of these cells in releasing
collagen and migrating to close wound scratch, and these effects
were completely reversed by P2X7R antagonists pre-incubation.
Notably, such changes took place only when receptor activation
occurred in the setting of a cell priming with LPS. This datum
first suggested that inflammatory molecules could represent
crucial mediators in the genesis of the phenomenon. Indeed,
it is well-recognized that in monocytes LPS-induced release of
inflammatory cytokines, particularly IL-1β and IL-6, is markedly
boosted by P2X7R activation (Di Virgilio, 2007; Castrichini et al.,
2014; Gicquel et al., 2015). Moreover, both these molecules are
produced by dermal fibroblasts upon LPS stimulation, (Tardif
et al., 2004; Wang et al., 2011) and are able to induce a fibrogenic
phenotype in these cells (Goldring and Krane, 1987; O’Reilly
et al., 2014). Despite such premises, our data conflict with
this interpretative hypothesis: LPS+BzATP incubation of SSc
fibroblasts did not produce any change in IL-1β release, while
IL-6, although reaching significantly higher levels with respect to
basal conditions (but still quite low in absolute), did not show any
appreciable impact on collagen production. In fact, reproducing
the in vivo conditions by adding the sIL-6R to cell cultures in
order to make possible IL-6-dependent transsignaling pathway
activation, no any further increase in PIP levels was detected.
As regards the apparently unexpected IL-1β findings, it should
be noted that previous studies demonstrated that IL-1α, rather
than IL-1β, peculiarly plays an important role in promoting the
activation of SSc dermal fibroblasts (Kawaguchi, 1994; Higgins
et al., 1999; Hutyrová et al., 2004; Kawaguchi et al., 2004). In
fact, while it has been reported that IL-1α is expressed in these
cells where induced a fibrogenic phenotype via an autocrine
mechanism (Kawaguchi et al., 2004), IL-1β was not detectable in
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both SSc fibroblast cell extracts and the supernatants (Kawaguchi,
1994).
An alternative intriguing mechanism by which the P2X7R
could promote the development of a fibrogenic phenotype in
fibroblasts may be the direct activation of intracellular pathways
controlling collagen biosynthetic machinery, particularly the
mitogen-activated protein kinase (MAPK) cascade. In fact,
increasing evidence indicates that a key role in fibroblast
activation is also played by ERK1/2, a member of the MAPK
family (Mu et al., 2012). Specifically, it has been demonstrated
that in SSc fibroblasts ERK1/2 activation contributes to increase
the expression of fibrotic proteins, including collagen, as well as
to the contraction of these cells (Bogatkevich et al., 2007; Chen
et al., 2008; Lazzerini et al., 2012).
Several data suggest that the P2X7R can activate the ERK1/2
pathway in different cell types, although the mechanism of this
coupling is still unclear (Amstrup and Novak, 2003; Gendron
et al., 2003). Intriguingly, in addition of being activated by
an increase in [Ca2+]i (Gendron et al., 2003), it has been
demonstrated that a sequence of the carboxy-end of the P2X7R
contains a conserved LPS-binding domain (Coddou et al., 2011),
and peptides derived from this sequence bind LPS in vitro and
neutralize the ability of LPS to activate ERK1/2 in tissue cultured
macrophages (Denlinger et al., 2001). Keeping this in mind,
the carboxy-terminal domain of P2X7R may directly coordinate
key signal transduction events related to LPS action also in
SSc fibroblasts, specifically the ERK1/2 activation, eventually
leading to the development of a pro-fibrotic phenotype. Our
data support this point of view. Indeed, we demonstrated that
LPS priming is required for P2X7R-induced collagen production
from SSc cells, and that such an effect was completely abrogated
when cultures were pre-incubated with a ERK1/2 inhibitor.
The concomitant finding here provided that also CTGF release
was induced by LPS+BzATP, and then fully reversed by both
P2X7R antagonists and ERK1/2 inhibitors, points to MAPK-
dependent CTGF production as a key event in promoting the
P2X7R-induced fibrogenic phenotype in dermal fibroblasts. This
hypothesis is supported by the evidence provided by Leask et al.
(2003) that MAPK pathway activation can induce the CTGF
promoter in human dermal fibroblasts.
Finally, we cannot ruled out that also indirect effects
can contribute to the observed P2X7R-induced ERK1/2
signaling activation and profibrotic response. In fact, it has
been demonstrated that P2X7R activation causes ATP release
(Pellegatti et al., 2005; Brandao-Burch et al., 2012), which in turn
can activate profibrotic P2Y2 and/or A2A receptors (in this case
indirectly, by increasing extracellular adenosine concentrations),
both exerting their effects through a MAPK signaling pathway
(Pellegatti et al., 2011; Lazzerini et al., 2012; Lu et al., 2012).
In conclusion, our data provide for the first time evidence
that in dermal fibroblasts from SSc patients both the expression
and function of the P2X7R are increased with respect to
healthy controls. In these cells, P2X7R stimulation induces a
fibrogenic phenotype characterized by increased migration
and collagen production, via activation of the ERK1/2
pathway. These findings, besides giving new insights on
the pathophysiology of SSc-associated dermal fibrosis, rise
the distinct possibility that drugs specifically blocking the
P2X7R could represent a novel and attractive pharmacological
target for anti-fibrogenetic therapy of the disease. Indeed,
novel P2X7R inhibitors are available for clinical use [e.g.,
periodate-oxidized ATP, (Ferrero, 2009) CE-224,535, (Stock
et al., 2012) and AZD9056 (Eser et al., 2015)]. Thus,
P2X7R targeting may have translational potential with a
possible relevant impact in morbidity and mortality in SSc
patients.
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